Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma
Phase 1
15
about 1.9 years
18+
1 site in CA
What this study is about
This trial is testing the safety, side effects, best dose and effectiveness of mezigdomide (CC-92480) when given after idecabtagene vicleucel (Abecma chimeric antigen receptor [CAR] T-cell therapy) in patients with multiple myeloma that has come back after a period of improvement (relapsed). Mezigdomide may extend the time CAR T cells persist in the body in relapsed multiple myeloma.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Mezigdomide
- 2.Undergo Biospecimen Collection
- 3.Undergo Bone Marrow Aspiration
- +2 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Incidence of adverse events
Secondary: Complete response rate, Duration of response, Overall response rate, Overall survival, Progression free survival, Time to progression
diagnostic, biopsy, imaging
Oncology